Section 13.2: HBOT, Biophysical Agents & Advanced Biologics

Section 13.2: Hyperbaric Oxygen Therapy (HBOT) & Advanced Biologics

When chronic wounds fail to progress through the normal phases of wound healing despite 30 days of optimal standard wound care (including debridement, moisture balance, infection control, and off-loading or compression), advanced adjunctive therapies are indicated. Among the most potent advanced modalities are Hyperbaric Oxygen Therapy (HBOT), Cellular and Tissue-based Products (CTPs / Skin Substitutes), and Autologous Blood-Derived Therapies such as Platelet-Rich Plasma (PRP). Mastery of the physiological principles, CMS coverage guidelines, structural properties, and application protocols of these therapies is essential for the ABWM Certified Wound Specialist (CWS).

---

Hyperbaric Oxygen Therapy (HBOT): Physiological Principles

Hyperbaric Oxygen Therapy involves the systemic administration of 100% medical-grade oxygen to a patient breathing inside a pressurized hyperbaric chamber (monoplace or multiplace) at ambient pressures greater than 1.0 Atmosphere Absolute (ATA), typically between 2.0 and 2.5 ATA.

Physical Laws & Dissolved Plasma Oxygen

Under normal atmospheric conditions (1.0 ATA at sea level), human arterial blood oxygen content is almost entirely determined by hemoglobin saturation (SaO2 ~98%), with a very small amount of dissolved oxygen in blood plasma (approximately 0.3 mL O2 per 100 mL of plasma or 0.3 vol%).

According to Henry's Law, the amount of gas dissolved in a liquid is directly proportional to the partial pressure of that gas above the liquid.

• When a patient inhales 100% O2 at 2.0 to 2.5 ATA, arterial oxygen tension (PaO2) increases from normal levels of ~100 mmHg to over 1500–2000 mmHg.
• This massive partial pressure gradient drives dissolved plasma oxygen concentrations up to 5.5 to 6.0 mL O2 per 100 mL of plasma (a 20-fold increase).
• Crucially, this quantity of dissolved plasma oxygen is sufficient to meet total resting cellular metabolic demands without any contribution from hemoglobin. Consequently, oxygen can diffuse up to four times deeper into hypoxic, microvascularly compromised wound tissues where red blood cells cannot physically pass.

Cellular Mechanisms of HBOT

1. Hyperoxia-Induced Angiogenesis: HBOT creates steep oxygen gradients between normoxic vascularized tissue and the central hypoxic wound core. This oxygen gradient stimulates endothelial cells and macrophages to release Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), and basic fibroblast growth factor (bFGF), triggering neovascularization.
2. Enhancement of Leukocyte Bactericidal Function: Neutrophils require molecular oxygen to produce reactive oxygen species (ROS) via the NADPH oxidase system (the oxidative burst). Hypoxic wound beds (TcPO2 < 20 mmHg) paralyze neutrophil bacterial killing. HBOT restores tissue oxygen levels above 30–40 mmHg, reinstating neutrophil phagocytosis and killing of aerobic pathogens (especially Staphylococcus aureus and Pseudomonas aeruginosa).
3. Suppression of Clostridial Toxins & Anaerobic Pathogens: High tissue oxygen tensions directly inhibit anaerobic bacterial replication and shut down alpha-toxin production in Clostridium perfringens (gas gangrene).
4. Fibroblast Proliferation & Collagen Synthesis: Prolyl and lysyl hydroxylase enzymes require molecular oxygen as a co-substrate to cross-link procollagen into mature triple-helix collagen fibers. HBOT provides necessary O2 for extracellular matrix building.
5. Stem Cell Mobilization: HBOT induces nitric oxide synthase activity in bone marrow, mobilizing autologous CD34+ vasculogenic stem cells into systemic circulation.

---

Approved CMS Indications & Clinical Protocols

The Centers for Medicare & Medicaid Services (CMS) strictly regulates reimbursement for HBOT. Candidates must meet specific diagnostic criteria and document failure of prior standard therapy.

---

Cellular and Tissue-Based Products (CTPs / Skin Substitutes)

Cellular and Tissue-based Products (CTPs), historically termed "skin substitutes," encompass a diverse spectrum of biologically derived matrices and living cellular constructs designed to replace, repair, or stimulate host extracellular matrix (ECM).

Classification & Biomaterial Sources

CTPs are categorized by their cellular composition, structural layering, and tissue origin:

1. Human Amniotic and Chorionic Membrane Derivatives (dHACM):
   • Structure: Dehydrated or cryopreserved human amnion/chorion tissue harvested from screened, elective post-cesarean placenta donors.
   • Composition: Retains native basement membrane, collagen types I, III, IV, V, fibronectin, laminin, and over 300 active growth factors and cytokines (PDGF, TGF-beta, VEGF, bFGF, TIMPs).
   • Mechanism: Provides a non-immunogenic structural scaffold while delivering sustained anti-inflammatory, anti-microbial, and pro-angiogenic signals to recalcitrant wound beds.
2. Bilayered Living Cell Constructs (e.g., Apligraf):
   • Structure: Composed of an upper epidermal layer formed by living human neonatal keratinocytes and a lower dermal layer composed of living human neonatal fibroblasts embedded in a bovine type I collagen matrix.
   • Mechanism: Acts as a "living drug delivery system." Living keratinocytes and fibroblasts actively respond to the wound environment by synthesizing and secreting balanced arrays of cytokines, matrix metalloproteinases, and growth factors. Indicated for DFUs and Venous Leg Ulcers (VLUs).
3. Single-Layer Living Dermal Constructs (e.g., Dermagraft):
   • Structure: Human neonatal fibroblasts cultured on a bioabsorbable polyglactin mesh scaffold.
   • Mechanism: Cryopreserved fibroblasts become metabolically active upon thawing and placement, depositing human collagen, fibronectin, and growth factors to rebuild damaged dermis in full-thickness DFUs.
4. Acellular Dermal Matrices (ADMs - Allografts & Xenografts):
   • Structure: Human cadaveric dermis (allograft) or porcine/bovine/fetal bovine dermis/peritoneum (xenograft) processed via decellularization to remove all cellular antigens while preserving the native 3D extracellular matrix architecture.
   • Mechanism: Serves as a durable dermal template for host cell infiltration, fibrovascular ingrowth, and re-epithelialization.

---

Platelet-Rich Plasma (PRP) & Autologous Blood Products

Platelet-Rich Plasma (PRP) is an autologous biologic therapy prepared by centrifuging whole blood to concentrate platelets above baseline systemic concentrations (typically 3- to 7-fold baseline, or >1,000,000 platelets/µL).

Biological Cascade & Growth Factor Release

Upon activation with thrombin, calcium chloride, or collagen, concentrated platelets undergo degranulation, releasing stored pre-formed growth factors from their alpha-granules:

• Platelet-Derived Growth Factor (PDGF): Potent chemoattractant for neutrophils, macrophages, and fibroblasts; stimulates angiogenesis and fibrogenesis.
• Transforming Growth Factor-Beta (TGF-beta): Stimulates extracellular matrix synthesis and collagen production.
• Vascular Endothelial Growth Factor (VEGF): Promotes microvascular endothelial cell proliferation and tubulogenesis.
• Epidermal Growth Factor (EGF): Accelerates keratinocyte migration and re-epithelialization.

Clinical Application Protocol

PRP can be formulated as a liquid for injection into chronic wound margins or combined with thrombin/calcium to form a PRP gel matrix that is applied directly to the wound bed. It is particularly valuable for recalcitrant neuropathic foot ulcers and chronic non-healing surgical wounds where autologous signaling is severely blunted.

---

Clinical Case Vignette

Clinical Scenario: A 62-year-old male with a 12-year history of poorly controlled type 2 diabetes presents with a non-healing plantar ulcer over the head of the first metatarsal measuring 2.5 cm × 2.0 cm × 0.8 cm. Probe-to-bone testing is positive, and MRI confirms osteomyelitis of the first metatarsal head. Vascular workup shows ABI 0.95. The patient completes surgical resection of the infected bone and 6 weeks of culture-directed IV vancomycin. However, at 30 days post-op, a clean, non-healing Grade 3 wound deficit remains without evidence of active infection.

Clinical Analysis: The patient has a Wagner Grade 3 DFU that has failed 30 days of documented standard therapy following surgical resolution of osteomyelitis. Under CMS criteria, this patient meets the exact requirements for adjunctive Hyperbaric Oxygen Therapy (HBOT) (30–40 sessions at 2.0–2.5 ATA). Furthermore, once a clean, vascularized wound bed is achieved, applying a Cellular and Tissue-based Product (CTP) such as dHACM or Apligraf can accelerate definitive wound closure.

---

Biophysical Technologies: Electrical Stimulation & Therapeutic Ultrasound

ABWM Domain 3 (Patient Management) explicitly tests biophysical technologies, including electrical stimulation and ultrasound. These modalities are adjuncts for stalled chronic wounds after etiology, perfusion, infection, and off-loading have been addressed—not stand-alone cures.

Electrical Stimulation (E-Stim)

High-voltage pulsed current (HVPC) is the most commonly studied waveform in wound care. Proposed mechanisms include:

• Galvanotaxis (directional migration of neutrophils, macrophages, and fibroblasts along an electrical gradient)
• Increased local perfusion and angiogenesis signaling
• Reduced local edema and bacterial burden in some laboratory models
• Support for collagen deposition and epithelial migration when the wound edge is viable

Practical clinical framing for the exam:

• Use as an adjunct for chronic pressure injuries, venous ulcers, or neuropathic ulcers that fail to progress despite optimized standard care.
• Electrodes are typically placed to deliver current through or around the wound bed per protocol; polarity strategies may change as healing progresses (clinicians follow device/protocol guidance rather than memorizing brand-specific settings).
• Contraindications / cautions: malignancy in the treatment field, untreated osteomyelitis, placement over the carotid sinus or through the heart/pacemaker pathway, active deep vein thrombosis in the treatment region, and pregnancy (abdominal/lumbar fields). Always follow facility policy and manufacturer labeling.

Therapeutic Ultrasound

Distinguish therapeutic ultrasound used as a healing adjunct from low-frequency ultrasound used primarily for debridement:

• Contact therapeutic ultrasound (typically 1–3 MHz in rehab settings) delivers mechanical energy that may influence cell membrane signaling, local circulation, and scar remodeling when applied around chronic wounds as an adjunct.
• Non-contact low-frequency ultrasound (NCLFUS) and ultrasonic debridement devices use saline mist or probe energy to disrupt biofilm/slough and cleanse the bed; on the blueprint these often sit at the intersection of biophysical therapy and wound bed preparation.
• Avoid treating over reproductive organs, eyes, CNS tissue, or sites of known malignancy; use caution over epiphyseal plates in children and over areas of acute untreated infection without a concurrent infection plan.

Exam Decision Rule

When a vignette describes a stalled but adequately perfused, off-loaded, and debrided wound, biophysical adjuncts (HVPC e-stim or therapeutic/NCLFUS ultrasound) are reasonable next-step options alongside—not instead of—compression, moisture balance, nutrition, and etiology control. Prefer revascularization, infection source control, or pressure relief first when those deficits are still present.